{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:56:57Z","timestamp":1788292617769,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The use of a liquid biopsy to assess molecular residual disease (MRD) of solid tumors holds significant promise for improving outcomes for patients with cancer. Liquid biopsies are a minimally invasive approach for the identification of circulating tumor biomarkers through a simple blood sample. Assays capable of detecting MRD through analysis of circulating tumor DNA (ctDNA) are rapidly evolving for clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC\u2014a multi\u2010disciplinary consortium representing stakeholders from public, industry, academia, and regulatory agencies\u2014formulated a lexicon that provides a shared framework and clear definitions using liquid biopsies for solid tumor MRD with an emphasis on ctDNA detection. The terms in the lexicon are categorized under general MRD, ctDNA testing methodologies, reporting results, and acquisition timepoints, including examples of current and potential clinical use cases for MRD tests. The overall goal is to provide a unified language and approaches to solid tumor MRD to advance applications of these technologies, allow data aggregation to strengthen future evidence, and facilitate regulatory approvals, leading to the use of liquid biopsy as an early endpoint in clinical trials. We believe that a common set of terminology and methods for solid tumor MRD can improve understanding and appropriate use of testing, accelerate clinical development, and improve outcomes for cancer patients.<\/jats:p>","DOI":"10.1111\/cts.70185","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:59:44Z","timestamp":1741769984000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6274-0555","authenticated-orcid":false,"given":"Andrew G.","family":"Hadd","sequence":"first","affiliation":[{"name":"Natera  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-7999","authenticated-orcid":false,"given":"Angela","family":"Silvestro","sequence":"additional","affiliation":[{"name":"GSK  Waltham Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-7153","authenticated-orcid":false,"given":"Brittany Avin","family":"McKelvey","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Baden","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Lawrence Township New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9586-0621","authenticated-orcid":false,"given":"Christina","family":"Bormann Chung","sequence":"additional","affiliation":[{"name":"GRAIL, Inc.  Menlo Park California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Brown","sequence":"additional","affiliation":[{"name":"Adela Bio  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7210-6603","authenticated-orcid":false,"given":"Fernando","family":"Cruz\u2010Guilloty","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Godsey","sequence":"additional","affiliation":[{"name":"Quest Diagnostics  Secaucus New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Jones","sequence":"additional","affiliation":[{"name":"NeoGenomics  Fort Myers Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng\u2010Ho Jimmy","family":"Lin","sequence":"additional","affiliation":[{"name":"Freenome  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1415-3135","authenticated-orcid":false,"given":"Dorys","family":"Lopez Ramos","sequence":"additional","affiliation":[{"name":"BLOODPAC  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Norton","sequence":"additional","affiliation":[{"name":"Personalis  Fremont California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie R.","family":"Palomares","sequence":"additional","affiliation":[{"name":"Exact Sciences  Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Pena","sequence":"additional","affiliation":[{"name":"Merck &amp; co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6930","authenticated-orcid":false,"given":"Thereasa","family":"Rich","sequence":"additional","affiliation":[{"name":"Guardant Health  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Natera  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4847-0736","authenticated-orcid":false,"given":"Mark","family":"Stewart","sequence":"additional","affiliation":[{"name":"Friends of Cancer Research  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-6957","authenticated-orcid":false,"given":"Diana","family":"Merino Vega","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4374-7246","authenticated-orcid":false,"given":"Lauren C.","family":"Leiman","sequence":"additional","affiliation":[{"name":"BLOODPAC  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12065"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.51700"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02301"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.943253"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104242"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051579"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00181"},{"key":"e_1_2_9_9_1","volume-title":"BEST (Biomarkers, EndpointS, and Other Tools) Resource","author":"Group FNBW","year":"2021"},{"key":"e_1_2_9_10_1","unstructured":"\u201cCirculating_Tumor_DNA_in_Development_of_Therapies_for_Cancer\u2010Evidentiary_Roadmap.pdf \u201daccessed October 21 2024 https:\/\/friendsofcancerresearch.org\/wp\u2010content\/uploads\/Circulating_Tumor_DNA_in_Development_of_Therapies_for_Cancer\u2010Evidentiary_Roadmap.pdf."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00382"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010023\u201006225\u2010y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102008\u201007\u2010077958"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520"},{"key":"e_1_2_9_15_1","unstructured":"Oncology Center of Excellence \u201cUse of Circulating Tumor Deoxyribonucleic Acid for Early\u2010Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability \u201dMay 2 2022 accessed October 21 2024 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/use\u2010circulating\u2010tumor\u2010deoxyribonucleic\u2010acid\u2010early\u2010stage\u2010solid\u2010tumor\u2010drug\u2010development\u2010draft\u2010guidance."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00274"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00167"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40246\u2010023\u201000533\u20100"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201040611\u2010w"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.074"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP\u201024\u201000481"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33924"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102022\u2010005344"},{"key":"e_1_2_9_25_1","unstructured":"B.Schneider \u201cA Phase II Circulating Tumor DNA Enriched Genomically Directed Post\u2010Neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE) \u201d2024accessed October 21 2024 https:\/\/clinicaltrials.gov\/study\/NCT04849364."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201051316\u20107"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T06:53:20Z","timestamp":1743317600000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1111\/cts.70185"],"URL":"https:\/\/doi.org\/10.1111\/cts.70185","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70185"}}